-Reuters
BioMarin Sells Priority Review Voucher For $110M
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)
Related Posts
Former State Lawmaker Wants To Make Bitcoin Legal Tender In California
A former state lawmaker in California would like to make Bitcoin (CRYPTO: BTC) legal tender in his state.
Beyond Meat Needs To Go Above And Beyond To Combat The Headwinds
For most of 2020, the pandemic-shaped year, COVID-19 wreaked havoc on the food and restaurant industry.